Agios Pharmaceuticals, Inc. (AGIO) financial statements (2020 and earlier)

Company profile

Business Address 88 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:541805568574376467194
Cash and cash equivalents8271103161721472
Short-term investments 51532138124532895
Other undisclosed cash, cash equivalents, and short-term investments459220144325912527
Receivables(1)(0) 5813 
Inventory, net of allowances, customer advances and progress billings61    
Inventory61     
Contract with customer, asset7 
Other undisclosed current assets(63)(192)(123)(19)(47)(121)(24)
Total current assets:490614445560337360170
Noncurrent Assets
Operating lease, right-of-use asset96
Property, plant and equipment242424252364
Long-term investments and receivables 220144325912527
Long-term investments 220144325912527
Restricted cash and investments      1
Other noncurrent assets 012110
Other undisclosed noncurrent assets89      
Total noncurrent assets:208245169598313231
TOTAL ASSETS:699858614619420492201
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities68605749313115
Accounts payable2218231715114
Accrued liabilities4742343216147
Employee-related liabilities     64
Taxes payable      1
Deferred revenue17
Debt7      
Deferred compensation liability      0
Deferred revenue and credits13839223625
Other liabilities     0 
Other undisclosed current liabilities 33   (6)(4)
Total current liabilities:92949588536137
Noncurrent Liabilities
Long-term debt and lease obligation108      
Operating lease, liability108
Liabilities, other than long-term debt501814417222633
Deferred revenue and credits1814417222633
Deferred revenue50
Other undisclosed noncurrent liabilities 60     
Total noncurrent liabilities:1587714417222633
Total liabilities:250171239261756870
Stockholders' equity
Stockholders' equity attributable to parent448688376359345424131
Common stock0000000
Additional paid in capital1,8621,7941,175842630591245
Accumulated other comprehensive income (loss)0(2)(1)(0)(0)(0)0
Accumulated deficit(1,414)(1,105)(798)(483)(285)(167)(113)
Total stockholders' equity:448688376359345424131
Other undisclosed liabilities and equity      0
TOTAL LIABILITIES AND EQUITY:699858614619420492201

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues112944370596526
Revenue, net4370599226
Cost of revenue
(Cost of Goods and Services Sold)
(2)(1) (0)(0)(0)(0)
Gross profit:111934370596525
Operating expenses(529)(457)(364)(271)(178)(119)(64)
Other undisclosed operating income21 0000
Operating loss:(417)(362)(321)(201)(119)(54)(39)
Nonoperating income
(Investment Income, Nonoperating)
161663100
Other undisclosed income from continuing operations before equity method investments, income taxes    0  
Loss from continuing operations before equity method investments, income taxes:(401)(346)(315)(198)(118)(54)(39)
Other undisclosed loss from continuing operations before income taxes    (0)  
Loss from continuing operations before income taxes:(401)(346)(315)(198)(118)(54)(39)
Income tax expense (benefit)     0(1)
Net loss attributable to parent:(401)(346)(315)(198)(118)(54)(39)
Preferred stock dividends and other adjustments      (4)
Net loss available to common stockholders, diluted:(401)(346)(315)(198)(118)(54)(44)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(401)(346)(315)(198)(118)(54)(39)
Other comprehensive income1      
Comprehensive loss:(400)(346)(315)(198)(118)(54)(39)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2(1)(1)0(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(398)(347)(316)(198)(118)(54)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: